Esperion Therapeutics (ESPR) 'Significantly Undervalued' Despite Move - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Esperion Therapeutics (ESPR) Continues Surge Higher; Up 14% on Heavy Volume
February 7, 2017 12:51 PM ESTEsperion Therapeutics (NASDAQ: ESPR) continues its recent surge higher after Amgen recently announced positive results from their FOURIER trial that evaluates Repatha (evolocumab), an anti-PCSK9 antibody, in ASCVD patient.
Shares are up 14.3% today on volume that is running 8x the norm. The stock is up about 70% since the Amgen news.
... MoreMedicines Co. (MDCO), Esperion Therapeutics (ESPR) Gain After Amgen Reports Positive Cardiovascular Outcomes from Repatha Study
February 2, 2017 5:19 PM ESTMedicines Co. (NASDAQ: MDCO) and Esperion Therapeutics (NASDAQ: ESPR) gained post-market after Amgen said its FOURIER trial evaluating whether Repatha reduces the risk of cardiovascular events met its primary endpoint. Shares of Novelion Therapeutics (NASDAQ:... More
